Sirolimus Coated Balloon
Script error: No such module "Draft topics". Script error: No such module "AfC topic". Script error: No such module "AfC submission catcheck".
Introduction[edit]
A Sirolimus Coated Balloon (SCB) is an advanced medical device used in the field of interventional cardiology for treatment of coronary artery disease and peripheral artery disease.
The balloon is coated with sirolimus immunosuppressive drug that help to prevent restenosis a common issue where artery narrows again after it has been treated again with angioplasty.
Background[edit]
Sirolimus[edit]
Sirolimus, also known as rapamycin, is a macrolide compound with potent immunosuppressive and antiproliferative properties. It was originally used to prevent organ transplant rejection but has since been adapted in the use of Drug-eluting stent, and drug coated balloon. Its ability to inhibit the proliferation of smooth muscle cells makes it effective in preventing restenosis.
Drug Coated Balloon[edit]
Drug coated balloon[1](DCB) are category of a medical device designed to deliver therapeutic agents to deliver directly to the arterial wall during angioplasty procedures. Unlike drug- eluting stents, which remain inside the artery, DCBs deliver drugs and are then removed. This approach reduces the long-term complications associated with permanent implant.
Mechanism of action[edit]
The Sirolimus coating on the balloon is released under arterial wall upon inflation. This localized delivery of sirolimus inhibits the proliferation of smooth muscle cell, which is a key factor in development of restenosis. The drug's antiproliferative effects helps to maintain vessel patency by preventing re-narrowing of artery after the procedure.
Application[edit]
Coronary Artery Disease[edit]
In the treatment of CAD, SCBs are used in Percutaneous coronary intervention (PCI) to open narrowed or blocked coronary arteries. SCBs are particularly beneficial in cases where restenosis occurred after pervious interventions or in small vessels disease where stent placement may be challenging.
Peripheral Artery Disease[edit]
SCBs, are employed in treatment of PAD, which involves narrowing of arteries in limbs. The use of SCBs in PAD interventions help to improve the blood flow and reduces the incidence of restenosis, thereby enhancing patient's quality of life.
Clinical Evidence[edit]
Numerous clinical trials have demonstrated the efficiency and safety of SCBs. Studies have shown SCBs are effective in reducing restenosis and improving long term in both coronary and peripheral artery interventions. These findings support the use of SCB as viable alternative to traditional stenting in selected patient population.
Advantage[edit]
Reduces Restenosis Rates: SCBs significantly lower the risk of restenosis compared to plain ballon angioplasty.
No Permanent Implant: The absence of permanent implant reduces the risk of long-term complication such as stent thrombosis.
Enhance Vessel Healing: The localized delivery of sirolimus promotes better vessel healing and reduces inflammation.
Limitations[edit]
Drug Delivery Challenging: Ensuring consistent and adequate drug delivery to arterial wall can be challenging.
Limited duration of effect: The drug is delivered during the procedure, and its effect diminishes over time, which may necessitate repeated intervention is some cases.
Future Direction[edit]
Ongoing research aim to optimize the drug formulation and delivery mechanism of SCBs to enhance their efficacy and safety profiles. Innovations in balloon technology and drug coatings are expected to further improve patient outcome and expand the applications of SCBs in cardiovascular interventions.
Conclusion[edit]
Sirolimus Coated Balloon represents a significant advancement in treatment of coronary and peripheral artery disease. By combining the mechanical benefits in balloon angioplasty with the pharmacological effects of sirolimus, SCBs offers and effective solution for preventing restenosis and improving vascular health. As clinical evidence continues to grow, SCBs are poised to play an increasingly important role in interventional cardiology and Vascular medicine.
1. Windecker,S.,et al. " The impact of Drug-coated ballon in Interventional cardiology". Journal of American college of cardiology, vol.62 no.1 ,2013, pp.1-11
2. Xu,B,et al. "Clinical Efficacy of Sirolimus-Coated Balloons." International Journal of Cardiology, vol.220, 2016, pp.233-240
3. Lassen, J.F., et al. "Drug coated Balloon: A Breakthrough Technology in coronary and peripheral intervention". Circulation. vol.134, no.4, 2016, pp. 280-291.
4. Mathey, D.G., & Blesse, N."Sirolimus Coated Balloon Cathers for Coronary and Peripheral Artery Disease". Cardiology Journal, Vol.25, no.1, 2018, pp.35-42
5. Concept Medical. "MagicTouch SCB." Accessed July 29,2024.[2]
6. Medtronic. "Drug Coated Balloon Technologies." Accessed July 29,2024 [3]
7. Biotronik. "Drug Coated Balloon Technologies." Accessed July 29,2024 [4]
This article "Sirolimus Coated Balloon" is from Wikipedia. The list of its authors can be seen in its historical and/or the page Edithistory:Sirolimus Coated Balloon. Articles copied from Draft Namespace on Wikipedia could be seen on the Draft Namespace of Wikipedia and not main one.
- ↑ Science Direct, Drug Coated Balloon
- ↑ MagicTouch SCB Granted ‘Breakthrough Device Designation’ for the treatment of Small Coronary Artery Lesions.
- ↑ Medtronic
- ↑ Biotronik Drug Coated Balloon Technologies
